Aller au contenu
Radio Logo

BioSpace

BioSpace
Dernier épisode

284 épisodes

  • BioSpace

    Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight

    18/11/2026 | 22 min
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
  • BioSpace

    Can we finally get ahead of drug shortages?

    12/11/2026 | 20 min
    In this episode of Denatured, you'll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
    Host
    Jennifer C. Smith-Parker, Director of Insights, BioSpace
    Guests
    Christina Smolke, Co-founder & CEO, Antheia
    Kyle Pudenz, Senior Vice President, Head of Data & AI Product, Cencora
    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
  • BioSpace

    Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

    11/11/2026 | 23 min
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.
  • BioSpace

    Beyond the needle: The future of intratumoral therapy

    05/11/2026 | 21 min
    In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anti-cancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.
    Host
    Jennifer C. Smith-Parker, Director of Insights, BioSpace
    Guests
    Lewis Bender, President & CEO, Intensity Therapeutics
    Paul-Peter Tak, President, CEO and Board Director, Candel Therapeutics
    Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
  • BioSpace

    Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

    04/11/2026 | 23 min
    The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.
Plus de podcasts Science de la vie
À propos de BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Site web du podcast

Écoutez BioSpace, The Naked Scientists Podcast ou d'autres podcasts du monde entier - avec l'app de radio.fr

Obtenez l’app radio.fr
 gratuite

  • Ajout de radios et podcasts en favoris
  • Diffusion via Wi-Fi ou Bluetooth
  • Carplay & Android Auto compatibles
  • Et encore plus de fonctionnalités